These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25119656)

  • 21. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
    Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V
    Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective use of radioactive iodine (RAI) in thyroid cancer: No longer "one size fits all".
    Marti JL; Morris LGT; Ho AS
    Eur J Surg Oncol; 2018 Mar; 44(3):348-356. PubMed ID: 28545679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer.
    Bohinc BN; Perkins JM
    Curr Opin Oncol; 2014 Jan; 26(1):31-5. PubMed ID: 24225414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of patients with thyroid tumors; global trends, current status in Japan and clinical problems and questions].
    Nakamura H
    Nihon Rinsho; 2007 Nov; 65(11):1937-42. PubMed ID: 18018552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons learned from thyroglobulin concentrations after total thyroidectomy and radioactive iodine ablation for differentiated thyroid cancer.
    Gomez-Hernandez K; Ezzat S
    Clin Biochem; 2015 Aug; 48(12):747-8. PubMed ID: 26162496
    [No Abstract]   [Full Text] [Related]  

  • 27. Severe hyponatremia following radioactive iodine therapy in patients with differentiated thyroid cancer.
    Kim SK; Yun GY; Kim KH; Park SK; Choi HY; Ha SK; Park HC
    Thyroid; 2014 Apr; 24(4):773-7. PubMed ID: 24093878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality indicators for thyroid cancer surgery: current perspective.
    Liu RQ; Wiseman SM
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):919-28. PubMed ID: 27559618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinico-social factors to choose radioactive iodine dose in differentiated thyroid cancer patients: an Asian survey.
    Jabin Z; Kwon SY; Bom HS; Lin Y; Yang K; Inaki A; Dewi AR; Al-Ibraheem AN; Balooshi BA; San Luis TOL;
    Nucl Med Commun; 2018 Apr; 39(4):283-289. PubMed ID: 29381585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment and follow-up of low-risk patients with thyroid cancer.
    Schlumberger M; Borget I; Nascimento C; Brassard M; Leboulleux S
    Nat Rev Endocrinol; 2011 Aug; 7(10):625-8. PubMed ID: 21826103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    Momesso DP; Tuttle RM
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2115-2116. PubMed ID: 28586457
    [No Abstract]   [Full Text] [Related]  

  • 32. Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?
    Giovanella L; Cosma C; Plebani M
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2113-2114. PubMed ID: 28586450
    [No Abstract]   [Full Text] [Related]  

  • 33. Postoperative Unstimulated Thyroglobulin for the Decision to Use Radioactive Iodine in Patients with Low- or Intermediate-Risk Papillary Thyroid Carcinoma.
    Rosario PW
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):867-868. PubMed ID: 31407180
    [No Abstract]   [Full Text] [Related]  

  • 34. Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology.
    Pacini F; Brianzoni E; Durante C; Elisei R; Ferdeghini M; Fugazzola L; Mariotti S; Pellegriti G
    J Endocrinol Invest; 2016 Mar; 39(3):341-7. PubMed ID: 26264386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review.
    Guo MY; Wiseman JJ; Wiseman SM
    Expert Rev Anticancer Ther; 2021 Feb; 21(2):205-220. PubMed ID: 33176520
    [No Abstract]   [Full Text] [Related]  

  • 36. Radioactive Iodine Remnant Ablation: The Beta-knife Completion Thyroidectomy.
    Gulec S; Kuker R
    Mol Imaging Radionucl Ther; 2017 Feb; 26(Suppl 1):16-23. PubMed ID: 28117286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letter to the Editor: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation".
    Giovanella L; Ceriani L; Trimboli P
    J Clin Endocrinol Metab; 2017 May; 102(5):1783-1784. PubMed ID: 28482079
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of differentiated thyroid cancers].
    Leboulleux S; Berdelou A; Hartl D
    Rev Prat; 2017 Jun; 67(6):680-684. PubMed ID: 30512746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience.
    Wijewardene A; Gild M; Nylén C; Schembri G; Roach P; Hoang J; Aniss A; Glover A; Sywak M; Sidhu S; Learoyd D; Robinson B; Tacon L; Clifton-Bligh R
    Eur Thyroid J; 2021 Jul; 10(5):408-415. PubMed ID: 34540711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-thyrotropin-dependent thyroid secretion.
    Nicoloff JT; Spencer CA
    J Clin Endocrinol Metab; 1992 Aug; 75(2):343. PubMed ID: 1639932
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.